OTCPK:CGNH

Stock Analysis Report

Executive Summary

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has CardioGenics Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CGNH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

CGNH

0.7%

US Biotechs

-1.1%

US Market


1 Year Return

-66.3%

CGNH

14.0%

US Biotechs

17.9%

US Market

Return vs Industry: CGNH underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: CGNH underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

CGNHIndustryMarket
7 Day0%0.7%-1.1%
30 Day-19.3%5.6%1.4%
90 Day3.1%6.2%6.9%
1 Year-66.3%-66.3%14.9%14.0%20.3%17.9%
3 Year-21.2%-21.2%24.4%21.1%47.8%38.3%
5 Year-81.0%-81.0%3.8%-1.0%71.9%53.0%

Price Volatility Vs. Market

How volatile is CardioGenics Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CardioGenics Holdings undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether CardioGenics Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as CardioGenics Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of CGNH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through CardioGenics Holdings regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is CardioGenics Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CardioGenics Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has CardioGenics Holdings performed over the past 5 years?

23.7%

Historical Pharmaceuticals & Biotech annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, CardioGenics Holdings has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is CardioGenics Holdings's financial position?


In this section we usually analyse CardioGenics Holdings's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. CardioGenics Holdings has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of CGNH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when CardioGenics Holdings's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is CardioGenics Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CGNH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CGNH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CGNH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CGNH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CGNH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

19.1yrs

Average management tenure


CEO

Yahia Gawad (61yo)

23.1yrs

Tenure

US$119,449

Compensation

Dr. Yahia Abdul Gawad, MB, Ch.B., MD, MSc. has been Chief Executive Officer of CardioGenics Holdings Inc. (formerly, JAG Media Holdings Inc.) since 1997 and its Director since 1997. Dr. Gawad is the Founde ...


CEO Compensation Analysis

Compensation vs Market: Yahia's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD522.48K).

Compensation vs Earnings: Insufficient data to compare Yahia's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Yahia Gawad
Founder23.1yrsUS$119.45kno data
James Essex
Chief Financial Officer19.1yrsUS$28.67kno data
Linda Sterling
Corporate Secretary & Director11.1yrsno datano data

19.1yrs

Average Tenure

61yo

Average Age

Experienced Management: CGNH's management team is seasoned and experienced (19.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Yahia Gawad
Founder23.1yrsUS$119.45kno data
Linda Sterling
Corporate Secretary & Director11.1yrsno datano data
Julian Tabatznik
Acting Chairman11.1yrsno datano data
Robert Roberts
Member of Scientific Advisory Board9.7yrsno datano data
William Kostuk
Member of Scientific Advisory Board9.7yrsno datano data
Karim Murabet
Independent Director5.1yrsno datano data

10.4yrs

Average Tenure

61yo

Average Age

Experienced Board: CGNH's board of directors are seasoned and experienced ( 10.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

CardioGenics Holdings Inc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CardioGenics Holdings Inc
  • Ticker: CGNH
  • Exchange: OTCPK
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$957.175k
  • Shares outstanding: 142.86m
  • Website: https://www.cardiogenics.com

Number of Employees


Location

  • CardioGenics Holdings Inc
  • 6295 Northam Drive
  • Unit 8
  • Mississauga
  • Ontario
  • L4V 1W8
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CGNHOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 2009

Biography

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 00:28
End of Day Share Price2020/02/21 00:00
Earnings2016/01/31
Annual Earnings2015/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.